ArticleClinical ophthalmology (Auckland, N.Z.)2026
Novel Non-Valved Glaucoma Drainage Device with Reduced Inner Lumen Diameter: 6-Month Safety and Efficacy Outcomes.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Comparative In Vitro Evaluation of Tube Resistance in Glaucoma Drainage Devices with Intraluminal Polypropylene Threads.Bioengineering (Basel, Switzerland) · 2026Article
- Safety and Efficacy of the Ahmed ClearPath versus Ahmed ClearPath Small Tube at Six Months: A Retrospective Comparative Cohort Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the safety and clinical efficacy of the Ahmed ClearPath Methods: This retrospective chart review included 17 eyes that underwent ACP-ST implantation between February 25, 2025, and November 24, 2025. Surgical success was defined as a ≥20% reduction in IOP from baseline with a postoperative IOP >5 mmHg and no need for additional surgical intervention. Changes in IOP, glaucoma medication burden, and best-corrected visual acuity (BCVA) were evaluated through 6 months. Intraoperative and postoperative complications were recorded. Results: Fourteen eyes had available 6-month follow-up data. Mean IOP decreased from 27.19 ± 6.29 mmHg at baseline to 12.21 ± 5.45 mmHg at 6 months, representing a 55.1% reduction (P < 0.0001). Mean glaucoma medication use decreased from 3.35 ± 1.14 to 1.07 ± 0.99 medications, corresponding to a 68.1% reduction (P < 0.0001). Surgical success was achieved in all 14 eyes (100%) with available 6-month follow-up. No intraoperative complications occurred, and no cases of postoperative hypotony or IOP spikes were observed. Conclusion: These preliminary findings suggest that ACP-ST may achieve clinically meaningful reductions in IOP and glaucoma medication burden while maintaining a favorable short-term safety profile, as no cases of postoperative hypotony or IOP spikes were observed. However, given the retrospective design, small sample size, and limited duration of follow-up, further longitudinal studies with larger cohorts will be necessary to better evaluate the durability and long-term safety of ACP-ST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.